tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Aardvark Therapeutics’ Promising Progress and Market Potential: Analyst Recommends Buy
PremiumRatingsAardvark Therapeutics’ Promising Progress and Market Potential: Analyst Recommends Buy
1M ago
Aardvark Therapeutics Begins Phase 3 HERO Trial Dosing
Premium
Company Announcements
Aardvark Therapeutics Begins Phase 3 HERO Trial Dosing
1M ago
Aardvark Therapeutics doses first patient in HERO trial
Premium
The Fly
Aardvark Therapeutics doses first patient in HERO trial
1M ago
Aardvark Therapeutics reports Q3 EPS (75c), consensus (80c)
PremiumThe FlyAardvark Therapeutics reports Q3 EPS (75c), consensus (80c)
2M ago
Aardvark Thera sees cash, equivalents sufficient to fund operations into 2027
Premium
The Fly
Aardvark Thera sees cash, equivalents sufficient to fund operations into 2027
2M ago
Aardvark Therapeutics, Inc.: Undervalued Potential in the Obesity Treatment Market with Promising Pipeline
Premium
Ratings
Aardvark Therapeutics, Inc.: Undervalued Potential in the Obesity Treatment Market with Promising Pipeline
2M ago
Aardvark Therapeutics Showcases Obesity Research at ObesityWeek
PremiumCompany AnnouncementsAardvark Therapeutics Showcases Obesity Research at ObesityWeek
2M ago
Aardvark Therapeutics presents data on metabolic obesity pipeline programs
Premium
The Fly
Aardvark Therapeutics presents data on metabolic obesity pipeline programs
2M ago
Aardvark Therapeutics Advances PWS Treatment with ARD-101 Study
Premium
Company Announcements
Aardvark Therapeutics Advances PWS Treatment with ARD-101 Study
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100